Innate immunity and pathology of the critical patient
PRINCIPAL INVESTIGATORS
- Joan Sabater Riera
CLINICAL RESEARCHERS
- Luisa Corral Ansa
- Maria Paz Fuset Cabanes
- Francesc Esteve Urbano
- Eva Oliver Juan
- Xosé Luis Pérez Fernández
- Gabriel Jesus Moreno González
- Ana Rosa Ochagavía Calvo
POSTDOCTORAL RESEARCHERS
- Sara Olivera Ardid
PREDOCTORAL RESEARCHERS
- Ricard Soley Corderas
- Victor Daniel Gumucio Sanguino
Translational Medicine
Infectious disease and transplantation
Scientific production
15
PAPERS
Average IF: 9,653
8
LED PAPERS
Average IF: 4,987
4 PUBLICATIONS IN FIRST DECILE
10 PUBLICATIONS IN FIRST QUARTILE
13 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Galli,F;Bindo,F;Motos,A;Fernandez Barat,L;Barbeta,E;Gabarrus,A;Ceccato,A et al, Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients, Intensive Care Med., 2023;49(8):934-945, doi:10.1007/s00134-023-07161-1
- Riera,J;Barbeta,E;Tormos,A;Mellado Artigas,R;Ceccato,A;Motos,A;Fernandez Barat,L et al, Effects of intubation timing in patients with COVID-19 throughout the four waves of the pandemic: a matched analysis, Eur. Resp. J., 2023;61(3):doi:10.1183/13993003.01426-2022
- Pérez Galera,S;Bravo Ferrer,JM;Paniagua,M;Kostyanev,T;de Kraker,M;Feifel,J;Sojo Dorado,J et al, Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)., EClinicalMedicine, 2023;57101871-101871, doi:10.1016/j.eclinm.2023.101871
- Matuozzo,D;Talouarn,E;Marchal,A;Zhang,P;Manry,J;Seeleuthner,Y;Zhang,Y et al, Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19., Genome Med., 2023;15(1):22-22, doi:10.1186/s13073-023-01173-8
- Olivera Ardid,S;Bello Gil,D;Perez Cruz,M;Costa,C;Camoez,M;Dominguez,MA;Ferrero Alves,Y et al, Removal of natural anti-aGal antibodies elicits protective immunity against Gram-negative bacterial infections, Front. Immunol., 2023;141232924-1232924, doi:10.3389/fimmu.2023.1232924
Research highlights
PROJECTS
2 Ongoing competitive projects
4 Ongoing non competitive projects
2 Started clinical trials
6 Ongoing clinical trials
PUBLISHED WORKS
1 Clinical guideline
INNOVATION
2 Patents
2 Licenses
1 spin-off
Selected projects
- 2022-311-1. ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO (PARTICIPANTE E INVESTIGADOR) Y CONTROLADO CON PLACEBO EN EL QUE SE EVALÚAN LA SEGURIDAD, LA TOLERABILIDAD Y LA EFICACIA DE TIN816 EN PACIENTES ADULTOS CON RIESGO DE LESIÓN RENAL AGUDA TRAS UNA CIRUGÍA CARDÍACA. Novartis Farmacéutica, S.A. Budget: 123.832€. 2023- . PI: Sabater Riera, Joan.
- 20CEE013. ENVISION: Intelligent plug-and-play digital tool for real-time surveillance of COVID-19 patients and smart decision-making in Intensive Care Units. COMISSIÓ EUROPEA. Budget: 115.000€. 2020-2023. PI: Máñez Mendiluce, Rafael.
- CEE21011. COVend: Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19. COMISSIÓ EUROPEA. Budget: 114.101,66€. 2021-2024. PI: Máñez Mendiluce, Rafael.
- 2023-472-1. ESTUDIO DE VALIDACIÓN DEL TEST SEPTILOOP LATERAL FLOW ASSAY EN PACIENTES SÉPTICOS. ESTUDIO PROSPECTIVO OBSERVACIONAL. LOOP DIAGNOSTICS SL. Budget: 42.000€. 2023- . PI: Sabater Riera, Joan.
- 2022-208-1. ESTUDIO DE FASE IIA, MULTICÉNTRICO, DOBLE CIEGO (PARTICIPANTE E INVESTIGADOR), ALEATORIZADO Y CONTROLADO CON PLACEBO EN EL QUE SE INVESTIGAN LA FARMACOCINÉTICA, LA FARMACODINÁMICA, LA SEGURIDAD Y LA TOLERABILIDAD DE TIN816 EN EL TRATAMIENTO DE PACIENTES CON LESIÓN RENAL AGUDA ASOCIADA A SEPSIS. Novartis Farmacéutica, S.A. Budget: 15.424€. 2022- . PI: Sabater Riera, Joan.